ALC vs ASND
Alcon Inc vs Ascendis Pharma A/S — AI-powered side-by-side comparison
VS
ASND
Ascendis Pharma A/S
66
Buy
| Metric | ALC | ASND |
|---|
| AI Score |
68
|
66
|
| Price |
$75.39
|
$254.27
|
| P/E Ratio |
45.39×
|
26.92×
|
| ROE |
4.4%
|
134.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
88.2%
|
| Debt / Equity |
0.24×
|
1.84×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
56.3
|
| Beta |
0.703
|
0.382
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus ASND.
ALC leads by 2 points.
ALC scores 68/100 (Buy) versus ASND at 66/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
ASND Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 129.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 134.8% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 22.5x prices in significant intangible value — Value
- Debt-to-equity of 1.93 adds balance-sheet risk to the value case — Value